Stan Kugell

Our mission is to create, develop and deploy technologies to massively accelerate progress in life science research.

Our mission is to create, develop and deploy technologies to massively accelerate progress in life science research.

ALFAMA is a young pharmaceutical company dedicated to the development of small-molecule drugs for unmet medical needs. ALFAMA's carbon monoxide releasing molecules (CORMs) hold the promise of contributing decisively to the prevention and cure of diseases involving inflammatory, infectious, thrombotic and apoptotic processes. Animal data indicates that various CORMs can be effective against ailments such as acute liver failure, multiple sclerosis, rheumatoid arthritis, transplant rejection, myocardial infarction, stroke, NSAID-induced gastric ulcers, hypertension and infection by antibiotic-resistant strains of bacteria. The core of ALFAMA's science is developed at state-of-the-art research facilities in the metropolitan areas of Lisbon (Portugal), where the company originally started, and Boston (Massachusetts, USA), where the headquarters of the mother company Alfama, Inc. are located. ALFAMA's innovative science and agressive business approch have allowed the company to recruit top talent from around the world, even at its current early stage, and to gain control of all the intellectual property in its field.